Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo de estudio
Tipo del documento
Intervalo de año de publicación
1.
Cell Host Microbe ; 28(2): 273-284.e6, 2020 08 12.
Artículo en Inglés | MEDLINE | ID: mdl-32668218

RESUMEN

The clinical spectra of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) intersect to form a scantily defined overlap syndrome, termed pre-IBD. We show that increased Enterobacteriaceae and reduced Clostridia abundance distinguish the fecal microbiota of pre-IBD patients from IBS patients. A history of antibiotics in individuals consuming a high-fat diet was associated with the greatest risk for pre-IBD. Exposing mice to these risk factors resulted in conditions resembling pre-IBD and impaired mitochondrial bioenergetics in the colonic epithelium, which triggered dysbiosis. Restoring mitochondrial bioenergetics in the colonic epithelium with 5-amino salicylic acid, a PPAR-γ (peroxisome proliferator-activated receptor gamma) agonist that stimulates mitochondrial activity, ameliorated pre-IBD symptoms. As with patients, mice with pre-IBD exhibited notable expansions of Enterobacteriaceae that exacerbated low-grade mucosal inflammation, suggesting that remediating dysbiosis can alleviate inflammation. Thus, environmental risk factors cooperate to impair epithelial mitochondrial bioenergetics, thereby triggering microbiota disruptions that exacerbate inflammation and distinguish pre-IBD from IBS.


Asunto(s)
Antibacterianos/efectos adversos , Dieta Alta en Grasa/efectos adversos , Disbiosis/patología , Metabolismo Energético/fisiología , Enfermedades Inflamatorias del Intestino/microbiología , Síndrome del Colon Irritable/microbiología , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Disbiosis/inducido químicamente , Enterobacteriaceae/crecimiento & desarrollo , Microbioma Gastrointestinal , Humanos , Mucosa Intestinal/microbiología , Mucosa Intestinal/patología , Complejo de Antígeno L1 de Leucocito/metabolismo , Mesalamina/uso terapéutico , Ratones , Ratones Endogámicos C57BL , Mitocondrias/metabolismo , PPAR gamma/agonistas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA